A new therapy paradigm for prostate cancer founded on clinical observations.
Efficacy equivalent to that reported in other common adult solid tumors considered to be chemotherapy-sensitive has been reported with Docetaxel in patients with castrate-resistant prostate cancer. However, in contrast to other cancers, the expected increase in efficacy with the use of chemotherapy in earlier disease states has not been reported to date in prostate cancer. On the basis of these observations, we speculated that the therapy development paradigm used successfully in other cancers may not apply to the majority of prostate cancers. Several lines of supporting clinical and experimental observations implicate the tumor microenvironment in prostate carcinogenesis and resistance to therapy. We conclude that a foundation to guide the development of therapy for prostate cancer is required. The therapy paradigm we propose accounts for the central role of the tumor microenvironment in bone and, if correct, will lead to microenvironment-targeted therapy.
Department of Genitourinary Medical Oncology and David H Koch Center for Applied Research of Genitourinary Cancers, University of Athens, Athens, Greece.
Eleni
E
Efstathiou
Christopher J
CJ
Logothetis
D001859:Bone Neoplasms / Q000556:secondary; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D008954:Models, Biological; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy*; D043823:Taxoids / Q000627:therapeutic use
D043823:Taxoids; D000077143:Docetaxel